Hohnloser Stefan H, Vámos Máté, Diener Hans-Christoph
Klinische Elektrophysiologie, Med. Klinik III, Kardiologie, J. W. Goethe Universität Frankfurt.
Universitätsklinik für Neurologie, Essen.
Dtsch Med Wochenschr. 2015 May;140(10):750-5. doi: 10.1055/s-0041-102000. Epub 2015 May 13.
The development of the direct oral anticoagulants (DOACs) represents one of the major breakthroughs in modern medicine over the last decade. Compared to vitamin K antagonists, all DOACs (dabigatran as a thrombin-Inhibitor, rivaroxaban, apixaban and edoxaban as factor Xa inhibitors) are much easier to handle due to their pharmacological properties. All DOACS are more efficacious and safer as vitamin K antagonists as demonstrated in the pivotal studies in more than 71,000 patients. Particularly the much lower risk of intracerebral bleeding complications is the reason why the DOACs should be preferred over vitamin K antagonists in patients with non-valvular atrial fibrillation.
直接口服抗凝剂（DOACs）的研发是过去十年现代医学的重大突破之一。与维生素K拮抗剂相比，所有DOACs（达比加群作为凝血酶抑制剂，利伐沙班、阿哌沙班和依度沙班作为Xa因子抑制剂）因其药理特性而更易于使用。在超过71000名患者的关键研究中表明，所有DOACs作为维生素K拮抗剂更有效且更安全。特别是脑出血并发症风险低得多，这就是在非瓣膜性心房颤动患者中DOACs应优于维生素K拮抗剂的原因。
